Rhythm Pharmaceuticals price to book ratio RYTM

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: 59.7×
9-year median: 5.3×
Against its 9-year history: 91st; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.7× to 193×
Peer median: 13.2×

Rhythm Pharmaceuticals' price to book ratio is 59.7× as of Oct 23, 2026.

That is above its 9-year median of 5.3×, higher than on 91% of days in the last 9 years.

Over that time it ranged from 0.7× in May 2022 to 193× in May 2025.

The median for 10 large drugmakers of a similar size is 13.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	59.7×	37.2×	77.3×
2025	49.3×	44.6×	193×
2024	76.2×	11.9×	82.0×
2023	13.8×	3.6×	14.1×
2022	5.8×	0.7×	6.8×
2021	1.6×	1.4×	8.9×
2020	6.7×	2.2×	6.7×
2019	6.8×	3.1×	7.2×
2018	3.4×	3.1×	7.2×

Against its peers

Companies in Drug Manufacturers - General nearest Rhythm Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
RYTMRhythm Pharmaceuticals	59.7×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
AMRXAmneal Pharmaceuticals	197×
ALKSAlkermes plc.	4.0×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
LQDALiquidia	19.6×
Peer median	13.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Rhythm Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.